HIF1A and Miyoshi myopathy: Both VEGF and HIF could be a therapeutic target of anti-MM therapy with specific small-inhibitor molecules even if many common anti-MM drugs such as bortezomib and lenalidomide are able to inhibit HIF-1α activity and thalidomide-derived immunomodulatory drugs (IMiDs) including lenalidomide and pomalidomide which are per se antiangiogenetic drugs [45].